{
    "clinical_study": {
        "@rank": "139422", 
        "arm_group": {
            "arm_group_label": "Androxal", 
            "arm_group_type": "Experimental", 
            "description": "Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule.  Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2."
        }, 
        "brief_summary": {
            "textblock": "To determine the safety profile of Androxal in men with secondary hypogonadism."
        }, 
        "brief_title": "An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Secondary Hypogonadism", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "detailed_description": {
            "textblock": "This study is an open-label, multi-center Phase 3 extension study to evaluate the safety on\n      continued treatment with Androxal in subjects who completed either ZA-301 or ZA-302.  The\n      study requires 6 study visits (1 for an eye exam) and is approximately 7 months in duration.\n       Subjects will be treated for 26 weeks, starting at a daily dose of 12.5 mg.  At Visit 2\n      (Week 6) subjects who do not achieve morning T values \u2265450 ng/dL will be up-titrated to 25\n      mg.  Safety will be assessed by physical and visual acuity exams, slit lamp and fundoscopy,\n      refraction eye exams, clinical laboratory tests and adverse event reporting."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Successful completion of either ZA-301 or ZA-302\n\n        Exclusion Criteria:\n\n        \u2022 Any condition which, in the opinion of the Investigator, would make the Subject an\n        unsuitable candidate for enrollment in the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739582", 
            "org_study_id": "ZA-301EXT"
        }, 
        "intervention": {
            "arm_group_label": "Androxal", 
            "intervention_name": "Androxal", 
            "intervention_type": "Drug", 
            "other_name": "enclomiphene citrate"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Clomiphene"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "Sponsor corporate web page", 
            "url": "http://reprosrx.com"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Values of total morning testosterone levels at each visit", 
            "measure": "Testosterone levels", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739582"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Values of Follicle Stimulating Hormone (FSH) and Leutinizing Hormone (LH) at each visit", 
                "measure": "Follicle Stimulating Hormone and Leutinizing Hormone", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Changes in HbA1c, fasting plasma glucose (FPG), insulin, and homeostasis model assessment-insulin resistance (HOMA-IR) for those subjects with Type II diabetes", 
                "measure": "Diabetic Parameters", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Change in weight and BMI", 
                "measure": "Change in weight and body mass index (BMI)", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }
        ], 
        "source": "Repros Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Repros Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}